Publication: Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%
Program
Authors
Authors
Kilickap S.
ÖZGÜROĞLU M.
Sezer A.
Gümüş M.
Bondarenko I.
Gogishvili M.
TÜRK H. M.
Cicin I.
Bentsion D.
Gladkov O.
Advisor
Date
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Background: In the phase 3 EMPOWER-Lung 1 study, first-line cemiplimab monotherapy provided significant survival benefit versus chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. This exploratory subgroup analysis investigated the clinical outcomes of cemiplimab treatment in patients with advanced NSCLC with brain metastases. Methods: Patients with advanced NSCLC were randomized (1:1) to cemiplimab 350 mg every 3 weeks or four cycles of platinum doublet chemotherapy (NCT03088540). Patients with symptomatic radiotherapy-treated brain metastases were eligible to enroll. Of the 565 patients with confirmed PD-L1 expression ≥50%, 69 (12%) had brain metastases at baseline. Results: Patients with brain metastases who received cemiplimab had a median overall survival (OS) of 52.4 months compared with 20.7 months for those who received chemotherapy (hazard ratio [HR], 0.40; p =.0031) and a median progression-free survival (PFS) of 12.5 versus 5.3 months (HR, 0.33; p =.0002), respectively. Patients without brain metastases had a median OS of 24.3 months with cemiplimab versus 12.5 months with chemotherapy (HR, 0.63; p <.0001); their median PFS was 6.5 months versus 5.2 months (HR, 0.55; p <.0001), respectively. Cemiplimab was associated with a significant improvement in global health status/quality of life in all patients, including those with brain metastases. The cemiplimab safety profile was generally similar in all patients. Conclusions: In patients with advanced NSCLC with PD-L1 ≥50%, first-line cemiplimab monotherapy improved survival and patient-reported outcomes over chemotherapy for those who received prior radiotherapy for symptomatic brain metastases.
Description
Source:
Keywords:
Keywords
Tıp, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji, Yaşam Bilimleri, Moleküler Biyoloji ve Genetik, Sitogenetik, Sağlık Bilimleri, Temel Bilimler, Medicine, Internal Medicine Sciences, Internal Diseases, Oncology, Life Sciences, Molecular Biology and Genetics, Cytogenetic, Health Sciences, Natural Sciences, Klinik Tıp (Med), Yaşam Bilimleri (Life), Klinik Tıp, Biyokimya ve Moleküler Biyoloji, Clinical Medicine (Med), Life Sciences (Life), Clinical Medicine, Molecular Biology & Genetics, Biochemistry & Molecular Biology, Kanser Araştırmaları, Cancer Research, advanced NSCLC, brain metastases, cemiplimab, immunotherapy, PD-L1
Citation
Kilickap S., ÖZGÜROĞLU M., Sezer A., Gümüş M., Bondarenko I., Gogishvili M., TÜRK H. M., Cicin I., Bentsion D., Gladkov O., et al., "Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%", Cancer, cilt.131, sa.10, 2025